Material matter: HM43239, an acute myeloid leukaemia drug candidate, licensed out
DART
Hanmi Pharm. Co., Ltd.
Filed Aug 26, 2026 KST · Filing
· receipt 20260826800466
kstock has not written this one up.
The title above is a translation of the Korean form name; the filing itself is on DART, in
Korean.
Read the original on DART ↗Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory
Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항 (급성골수성백혈병(AML) 치료 항암신약 HM43239 기술이전 계약 체결)